Heart Institute, Teknon Medical Center, C/Vilana, 12, Barcelona, Spain.
Ospedale Guglielmo da Saliceto, Piacenza, Italy.
Europace. 2019 Jul 1;21(7):1079-1087. doi: 10.1093/europace/euz027.
Ablation of frequent premature ventricular complexes (PVCs) improves left ventricular ejection fraction in patients with left ventricular (LV) systolic dysfunction. This study aims to evaluate the long-term hard outcomes and potential prognostic variables in this population.
Prospective multicentre study including 101 consecutive patients [56 ± 12 years old, 62 (61%) men] with LV systolic dysfunction and frequent PVCs who underwent PVC ablation before November 2015. The last evaluation performed was considered the long-term follow-up (LTFUP) evaluation. Mean follow-up was 34 ± 16 months (range 24-84 months). Ablation was successful in 95 (94%) patients. There was a significant reduction in the PVC burden from 21 ± 12% at baseline to 3.8 ± 6% at LTFUP, P < 0.001. Left ventricular ejection fraction improved from 32 ± 8% at baseline to 39 ± 12% at LTFUP (P < 0.001) and New York Heart Association class from 2.2 ± 0.6% to 1.3 ± 0.6% (P < 0.001). Brain natriuretic peptide levels decreased from 136 (78-321) to 68 (32-144) pg/mL (P = 0.007). Most of this improvement occurs during the first 6 months after ablation. Persistent abolition of at least 18 points of the baseline PVC burden was independently and inversely associated with the composite endpoint of cardiac mortality, cardiac transplantation, or hospitalization for heart failure during follow-up [hazard ratio 0.18 (0.05-0.66), P = 0.01].
In patients with LV systolic dysfunction, ablation of frequent PVCs induces a significant improvement in functional, structural, and neurohormonal status, which persists at LTFUP. A sustained reduction in the baseline PVC burden is associated with a lower risk of cardiac mortality, cardiac transplantation, or hospitalization for heart failure during follow-up.
消融频发室性早搏(PVCs)可改善左心室收缩功能障碍患者的左心室射血分数。本研究旨在评估该人群的长期硬终点和潜在的预后变量。
前瞻性多中心研究纳入了 101 例连续患者(56±12 岁,62 例[61%]男性),这些患者在 2015 年 11 月前因左心室收缩功能障碍和频发 PVC 而接受 PVC 消融治疗。最后一次评估被认为是长期随访(LTFUP)评估。平均随访时间为 34±16 个月(范围 24-84 个月)。95 例(94%)患者消融成功。PVC 负荷从基线时的 21±12%显著降低至 LTFUP 时的 3.8±6%,P<0.001。左心室射血分数从基线时的 32±8%改善至 LTFUP 时的 39±12%(P<0.001),纽约心脏协会心功能分级从 2.2±0.6%改善至 1.3±0.6%(P<0.001)。脑钠肽水平从 136(78-321)pg/ml 降至 68(32-144)pg/ml(P=0.007)。这种改善大多发生在消融后 6 个月内。持续消融至少 18 个基线 PVC 负荷点与随访期间心脏死亡、心脏移植或心力衰竭住院的复合终点呈独立负相关[风险比 0.18(0.05-0.66),P=0.01]。
在左心室收缩功能障碍患者中,消融频发 PVC 可显著改善心功能、结构和神经激素状态,且在 LTFUP 中持续存在。消融后基线 PVC 负荷持续降低与随访期间心脏死亡、心脏移植或心力衰竭住院风险降低相关。